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Background: MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression.
Sequential cleavage of miRNA precursors results in a ~22 nucleotide duplex of which one strand, the mature
miRNA, is typically loaded into the RNA-induced silencing complex (RISC) while the passenger strand is degraded.
Very little is known about how genetic variation might affect miRNA biogenesis and function.
Results: We re-sequenced the MIR1-1, MIR1-2, MIR133A1, MIR133A2, and MIR133B genes, that encode the cardiac-
enriched miRNAs, miR-1 and miR-133, in 120 individuals with familial atrial fibrillation and identified 10 variants,
including a novel 79T > C MIR133A2 substitution. This variant lies within the duplex at the 30 end of the mature
strand, miR-133a-3p, and is predicted to prevent base-pairing and weaken thermostability at this site, favoring
incorporation of the passenger strand, miR-133a-5p, into RISC. Genomic DNA fragments containing miR-133a-2
precursor sequences with 79T and 79C alleles were transfected into HeLa cells. On Northern blotting the 79T allele
showed strong expression of miR-133a-3p with weak expression of miR-133a-5p. In contrast, the 79C allele had no
effect on miR-133a-3p but there was a significant increase (mean 3.6-fold) in miR-133a-5p levels. Deep sequencing
of small RNA libraries prepared from normal human and murine atria confirmed that nearly all the mature miR-133a
was comprised of miR-133a-3p and that levels of miR-133a-5p were very low. A number of isomiRs with variations
at 50 and 30 ends were identified for both miR-133a-3p and miR-133a-5p, with 2 predominant miR-133a-3p isomiRs
and one predominant miR-133a-5p isomiR. Bioinformatics analyses indicate that the major miR-133a-3p and 5p
isomiRs have numerous predicted target mRNAs, only a few of which are in common.
Conclusions: Multiple miR-133a isomiRs with potential different mRNA target profiles are present in the atrium in
humans and mice. We identified a human 79T > C MIR133A2 variant that alters miRNA processing and results in
accumulation of the miR-133a-5p strand that is usually degraded.
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MicroRNAs (miRNAs) are small non-coding RNAs that
regulate gene expression. They act by binding to the
30untranslated regions of target mRNAs and typically re-
duce mRNA levels by inhibiting translation or stimula-
ting mRNA decay [1]. MiRBase v18 [2] lists 2148 human* Correspondence: d.fatkin@victorchang.edu.au
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reproduction in any medium, provided the ormiRNAs, each of which is expected to have multiple
mRNA targets. Consequently, miRNAs can orchestrate
suites of changes in gene expression and have been im-
plicated in diverse normal physiological processes and
disease states [3].
Most miRNAs are transcribed from their own genes
by RNA polymerase II. A minority of miRNAs are lo-
cated within introns of other genes and are co-
transcribed with the host gene. In the canonical miRNA
biosynthesis pathway, primary miRNA (pri-miRNA)
hairpins are cleaved by the nuclear RNAase III-type
endonuclease Drosha to yield a ~70 nucleotide (nt) pre-
cursor miRNA (pre-miRNA) that is then exported to thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Dicer generates a ~ 22 nt mature miRNA duplex [4].
Typically, the dominant (mature) strand of the duplex is
incorporated into an RNA-induced silencing complex
(RISC) that binds to the target mRNA by sequence-
specific interactions between the “seed” region (nt 2–8)
at the 50 end of the miRNA and the cognate mRNA bind-
ing site. The remaining (passenger) strand of the duplex
is thought to be non-functional and degraded. Recent
deep sequencing data have revealed surprising additional
complexity of miRNA processing and have found that
multiple miRNA isoforms (isomiRs) of varying sequence
composition and length may be present [5-8].
The muscle-enriched miRNAs, miR-1 and miR-133,
are amongst the most abundant of the miRNAs present
in the normal heart [9,10]. Two genes, MIR1-1 and
MIR1-2, encode miR-1-1 and miR-1-2, while three
genes, MIR133A1, MIR133A2, and MIR133B, encode
miR-133a-1, miR-133a-2, and miR-133b, respectively.
MiR-133a-1 and miR-133a-2 have identical mature se-
quences, with miR-133b differing only by a single nt at
the 30 end. In humans, MIR1-1 and MIR133A2 are lo-
cated on chromosome 20 while MIR1-2 and MIR133A1
are located on chromosome 18. These 2 pairs of genes
are co-regulated and expressed as bicistronic transcripts.
MIR133B is on chromosome 6 and is paired with ano-
ther muscle-specific miRNA gene, MIR206. Verified
mRNA targets of miR-1 and miR-133 include those en-
coding proteins that are involved in cardiac develop-
ment, ion channel function, hypertrophy, and fibrosis
[11-16].
Atrial fibrillation (AF) is the most common cardiac
arrhythmia and a frequent complication of diverse car-
diac and systemic disorders. Altered levels of miR-1 and
miR-133 have been observed in atrial tissue samples
from patients with AF in several studies [17-19].
MiRNA-induced gene expression changes in the atrium
could either have a primary role in initiation of AF or
contribute to electrical and structural remodelling that
perpetuates AF. In this study, we hypothesized that gen-
etic variation could alter the functional effects of miR-1
and miR-133 and contribute to AF pathogenesis. To test
this hypothesis, we performed genetic screening of the
MIR1-1, MIR1-2, MIR133A1, MIR133A2, and MIR133B
genes in a cohort of probands with suspected familial
AF. A number of variants were identified, including a
novel MIR133A2 variant that was functionally character-
ized and found to alter miR-133a duplex processing. To
assess the potential effects of this variant, we first needed to
catalogue the abundance and diversity of miR-133a isomiRs
in the normal heart. Deep sequencing of human and mu-
rine atrial tissue was performed and revealed an unexpected
diversity of miR-133a isomiRs, with nearly all the miR-133a
tags comprised of the 2 major miR-133a-3p isomiRs and<1% comprised of miR-133a-5p species. Our data suggest
that the MIR133A2 variant increases the relative abundance
of miR-133a-5p.Results
MiR-1 and miR-133 sequence variants
The 5 loci encoding miR-1 and miR-133 precursor tran-
scripts were re-sequenced in 120 probands with a family
history of AF. Ten variants were identified, 2 of which
were novel (Table 1). For the 8 known variants, the
minor allele frequencies in the AF group were similar
to those reported in the public databases, dbSNP,
NHLBI Exome Variant Server and 1000 Genomes. Three
MIR133A2 variants, -102G >A, -82G >A, and -19G >A,
were in linkage disequilibrium as reported previously [20].
A MIR133A2 haplotype that included -102G >A, -82G >A,
-19G >A, and +47T >C was present on one allele in 18 AF
probands (15%) and 37 in-house controls (15%), and on
both alleles in 8 AF probands (7%) and 12 in-house con-
trols (5%). Of the 2 novel variants, only one was located
within a miRNA stem-loop sequence. This variant, a 79T
> C substitution in the MIR133A2 gene (Figure 1A), was
found in a 67-year old female (II-5, Family KB, Figure 1B)
who had paroxysmal episodes of AF, hypertension and
mitral valve disease. The two other living family mem-
bers with AF, II-1 and II-4, were genotype-negative.
The 79T > C variant was not seen in clinically un-
affected relatives, in our 250 healthy control subjects,
or in the human genome sequence databases.79T > C MIR133A2 variant increases levels of miR-133a-5p
The 79T > C MIR133A2 variant is positioned directly ad-
jacent to the Drosha cleavage site in the stem-loop struc-
ture at the 30 end of miR-133a-3p (Figure 1C). In the
absence of sequence data for human miR-133a-5p in
miRBase, this location was initially deduced from 3p
dominant processed sequence listed for mouse. We pre-
dicted that the mismatch introduced by the 79T > C sub-
stitution would alter secondary structure and thus
precursor processing and/or subsequent strand selection.
To test these predictions, we prepared two constructs
that replicated the 79T and 79C genotypes of mature
miR-133a, transfected these into the HeLa cell line that
does not detectably express endogenous miR-133a and
performed Northern blotting. For these studies, the
miR-133a-2 haplotype (−19G > A, +47T > C), which was
present in the proband, II-5, and her affected sister, II-4,
was used as the background sequence. The 79T allele
had strong expression of miR-133a-3p with low amounts
of miR-133a-5p. When compared with 79T, the 79C
allele showed no significant change in miR-133a-3p
(P = 0.81) but there was a mean 3.6-fold increase in
levels of miR-133a-5p (P = 0.003, Figure 1D).
Table 1 MiR-1 and miR-133 gene variants identified in familial AF probands
Gene Chromosome Nucleotidechangea
Major/Minor
allele
Minor allele frequencyb
dbSNPc
AF Controls ESP 1000G
MIR1-1 20 −43C > T C/T 0.004 NA - - Novel
MIR1-2 18 +15A > G A/G 0.017 NA 0.020 0.018 rs9989532
+74T > C T/C 0.046 NA 0.087 0.071 rs78641532
MIR133A2 20 −102G > A G/A 0.142 0.122 - 0.207 rs45547937
−82G > A G/A 0.142 0.122 - 0.206 rs13040566
−19G > A G/A 0.142 0.122 0.229 0.207 rs13040413
79T > C T/C 0.004 0 - - Novel
+47T > C T/C 0.400 0.340 0.388 0.387 rs6062251
+69G > A G/A 0.004 0.010 0.006 0.009 rs149629841
MIR133B 6 −25delA A/- 0.083 NA 0.075 0.074 rs142410335
a Location of nucleotide changes is shown as (−) downstream or (+) upstream of the miRNA stem-loop sequence (as annotated by miRBase).
b AF, atrial fibrillation (n = 120, this study cohort); Controls, healthy volunteer subjects (n = 250, this study cohort); ESP, NHLBI Exome Sequencing Project (European
American subgroup data); 1000G, 1000Genomes Project (European subgroup data). NA, data not available (not tested).
c dbSNP, Database of Single Nucleotide Polymorphisms [http://www.ncbi.nlm.nih.gov/projects/SNP/].
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To determine the diversity and abundance of miR-133a-3p
and 5p processed species that are normally present in the
atrium, small RNA libraries were prepared from human
and murine heart tissue samples and were subjected to
deep sequencing. A comprehensive list of the sequences
and expression levels of all the cardiac miRNA isomiRs
identified is provided in the (Additional file 1: Table S1
and Additional file 2: Table S2). In human and murine
atrial tissues, miR-133 was the most highly expressed
miRNA, comprising approximately 20% of all miRNA
sequences. Analysis of sequencing tags that map to a
miR-133a locus showed an extensive range of 50 and 30
isomiRs for miR-133a-3p and miR-133a-5p in both human
and mouse (Additional file 3: Table S3 and Additional file 4:
Table S4). There were two predominant isomiRs processed
from the miR-133a 3p arm in both the human and murine
atria (Figures 2A and 2B). The sequences for the
miR-133a high-abundance isomiRs were identical in the
two species. Together, the abundance of these tags repre-
sented >99% of all tags derived from the miR-133a hairpin.
Interestingly, the more abundant sequence in both human
and murine samples was not the sequence annotated as
the mature form in miRBase, but rather the +1 isomiR.
Less than 1% of all sequences that mapped to the
miR-133a hairpin aligned to the 5p arm. There was a
single predominant miR-133a-5p isomiR in human
atrium, which started one nt upstream from the murine
miRBase entry. There was also only one major murine
miR-133a-5p isomiR that had an identical 50 sequence to
the major human miR-133a-5p isomiR.
MiR-133a mRNA target profiles
We hypothesized that increases in miR-133a-5p asso-
ciated with the 79T > C MIR133A2 variant could resultin selective down-regulation of a distinctive set of target
mRNAs. To explore what these cardiac genes might be,
we used the seed sequences of the two most abundant
human miR-133a-3p isomiRs and the single abundant
miR-133a-5p isomiR identified by deep sequencing to
look for predicted human mRNA binding sites in
TargetScan. For the two abundant human miR-133a-3p
isomiRs, the seed sequences TGGTCCC and TTGGTCC
had 402 and 502 predicted targets, respectively, of which
247 were in common. Only 26 (6%) of the total 402
TGGTCCC human miR-133a-3p isomiR targets over-
lapped with the predicted targets for the abundant hu-
man miR-133a-5p, and similarly, 30 (6%) of the total 502
TTGGTCC isomiR targets overlapped with those pre-
dicted for human miR-133-5p. Overall, only 44 (7%) of
the total 657 human miR-133a-3p predicted targets from
both abundant isomiRs overlapped with the targets pre-
dicted for miR-133a-5p (Figure 2C). To compare murine
miR-133a-3p and miR-133a-5p targets, we used the two
predominant 3p and single predominant 5p murine
isomiR seed regions to search for predicted mRNA bind-
ing sites in TargetScan. Similar to the human data, only
a minority of murine miR-133a-3p targets (31 [5%])
overlapped with 5p targets (Figure 2D). When all
TargetScan-predicted targets were considered, there was
substantial concordance across species with 514 (78%)
of human miR-133a-3p targets and 259 (78%) of human
miR-133a-5p targets shared by mouse. We then cross-
referenced all the predicted murine targets to a set of
mRNAs identified by Liu and colleagues [21] that
showed altered expression levels in miR-133a knockout
mice. This produced a list of 61 predicted targets for
miR-133a-3p and 35 predicted targets for miR-133a-5p, only
4 of which were in common (Figure 2D). We also compared
our TargetScan outputs to a list of 1640 miR-133a
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Figure 1 Characteristics of the 79T > C MIR133A2 variant. (A) Sequence electropherograms with arrows indicating normal 79T allele (top
panel) and variant 79C allele (lower panel). (B) Family KB pedigree. Phenotypes are indicated as: AF (solid symbols), no AF (open symbols). The
presence (+) or absence (−) of the 79T > C MIR133A2 variant is shown and the family proband is indicated by an arrow. (C) Stem-loop region of
precursor miR-133a-2 transcript depicting the most abundant human isomiRs for miR-133a-3p (green) and miR-133a-5p (blue) with seed regions
indicated (bold). The 79T > C variant (red) is located at the 30end of miR-133a-3p directly adjacent to the Drosha cleavage site. (D) Northern blot
probed with miR-133a-3p (top panel) and miR-133a-5p (lower panel) showing expression levels of 79T and 79C alleles. Mean data for triplicates of
each sample are indicated on bar graphs with 79C values expressed relative to 79T values. *P <0.05 when compared to 79T.
Ohanian et al. BMC Genetics 2013, 14:18 Page 4 of 10
http://www.biomedcentral.com/1471-2156/14/18
TTGGTCCCCTTCAACCAGCTGT
TTTGGTCCCCTTCAACCAGCTGT
TGGTCCCCTTCAACCAGCTGT
ATTTGGTCCCCTTCAACCAG
GCTGGTAAAATGGAACCAAATA
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Figure 2 Abundance of miR-133a 50 isomiRs in atrial tissue. MiR-133a-3p (green) and miR-133a-5p (blue) isomiRs were evaluated by deep
sequencing of human (A) and murine (B) atrial tissues. 50 isomiRs affect the seed sequences and are considered functionally more important than 30
isomiRs. The most abundant 50 isomiRs, with the most frequently-occurring 30variant for each of these, are shown. MirBase-annotated miR-133a-3p and
5p sequences are shown in black with ‘seed’ regions (nt 2–8) underlined. Note that there is no miRBase annotation for human miR-133a-5p. (C) Venn
diagram showing numbers of human target mRNAs predicted by TargetScan with the seed regions of the 2 most abundant human miR-133a-3p
isomiRs and the single abundant miR-133a-5p isomiR used as inputs. (D) (Left panel) Murine target mRNAs predicted by TargetScan with seed regions
of the 2 abundant murine miR-133a-3p isomiRs and single abundant miR-133a-5p isomiRs as inputs. (Right panel) Venn diagram showing numbers of
putative miR-133a-3p and miR-133a-5p target mRNAs determined by cross-referencing predicted murine targets with genes demonstrated to be
differentially regulated in the hearts of miR-133a knockout mice [22].
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mouse heart using RISC-seq [16]. When the
TargetScan and RISC-seq data were compared, there
were 168 miR-133a-3p targets when considering both
major isomiRs, and 75 miR-133a-5p targets, only 6 of
which were common. Matkovich and colleagues reduced
their list of 1640 targets to 209 by analyzing transgenic
mice that overexpress miR-133a [16]. A comparison of
TargetScan targets with this refined list identified 27
miR-133a-3p targets when considering both major
isomiRS and 4 miR-133a-5p targets, with no targets
in common. These findings collectively suggest that
miR-133a isomiRs have distinctive target spectra. In the
Ingenuity Knowledge Base, the TargetScan-predicted
human miR-133a-3p and 5p target mRNAs are asso-
ciated with a range of cardiac and extra-cardiac bio-
logical functions (Figure 3).Discussion
There are two major outcomes of this study. First, we
have characterized atrial miR-133a species and find an
extraordinary diversity of 50 and 30 miR-133a-3p and
miR-133a-5p isomiRs, with two major 3p isomiRs and
one major 5p isomiR in both human and mouse. These
isomiRs have minimally-overlapping suites of predicted
mRNA targets and functions, which suggests that they
have distinct biological roles. Second, we report a novel
MIR133A2 variant that alters strand abundance during
miRNA processing and results in accumulation of miR-
133a-5p. This variant is one of only a very few functional
miRNA gene variants reported to date.
Despite the enormous interest in miRNAs as master
regulators of gene expression, the role of genetic va-
riation is incompletely understood. Single nucleotide
polymorphisms (SNPs) in predicted miRNA binding
Tachycardia
Cardiac Stress Response
Cardiac Necrosis/Cell Death
Cardiac Arrhythmia 
Cardiac Inflammation
Cardiac Enlargement
Heart Failure
Cardiac Congestive Cardiac Failure
Cardiac Hypoplasia
Cardiac Dilation
Cardiac Hypertrophy
Congenital Heart Anomaly 
miR-133a-3p miR-133a-5p
ExtracardiacCardiac CardiacExtracardiac
Figure 3 Functional analysis of human miR-133a-3p and miR-133a-5p targets. Significant associations were found in the Ingenuity
Knowledge Base between predicted human target mRNAs of miR-133a-3p and miR-133a-5p and a range of cardiac and extra-cardiac biological
functions and/or disease states. Parameters that achieved statistical significance (P < 0.05) are shown for miR-133a-3p (left) and miR-133a-5p
(right), with the relative proportions determined on the basis of the negative logarithm of the P values.
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these have been associated with phenotypic traits
[22-25]. In contrast, SNPs in the miRNA genes them-
selves are far less common. Several SNPs in pri-miRNA
and pre-miRNA have been functional evaluated and
shown to result in defective processing and reduced
levels of mature miRNA. SNPs are rarely seen (<1%) in
the seed regions that are crucially required for target
recognition [22]. These observations have provided an
argument for strong selective constraint and suggest that
seed variants would have substantial effects. The disco-
very of point mutations in the seed region of miR-96 in
two families with nonsyndromic progressive hearing loss
provided the first example of human Mendelian disease
associated with a miRNA gene variant [26]. Functional
SNPs can occur in mature miRNAs outside the seed re-
gion, as recently demonstrated by the finding of a rare
variant at nt 17 of miR-499 [27]. Evaluation of the effects
of this variant in transgenic mice showed that it
protected against the cardiomyopathy that developed
with overexpression of the wildtype form of miR-499.
Here we describe a MIR133A2 variant located in the ma-
ture miRNA outside the seed region that changes the
way that the miRNA duplex is processed.
MiRNA processing is conventionally assumed to yield
only one functional mature miRNA with the passenger
strand being degraded and hence, functionally irrelevant.
It has recently been appreciated however, that passenger
forms are not always selected for degradation, rather,
that both 3p and 5p strands of the miRNA duplex may
be simultaneously present and that their ratio can be
regulated in a tissue- or development-specific manner,suggesting that both strands have inherent functional ac-
tivity [28]. Here we find that both (mature) miR-133a-3p
and (passenger) miR-133a-5p are present in the atrium
in humans and mice, with miR-133a-5p normally
representing <1% of all miR-133a species. The main ef-
fect of the 79T > C MIR133A2 variant is to alter the rela-
tive ratio of miR-133a-3p and 5p strands.
Current models posit that the strand of the miRNA
duplex with weaker base-pairing at the 50 end is prefer-
entially incorporated into RISC [4]. If the conventional
murine miR-133a-5p sequence as annotated by miRBase
(v18) represented the predominant isomiR in the normal
human heart, then the nt corresponding to position 79
would lie just outside the base-paired region of the
processed miRNA duplex. However, our deep sequen-
cing data clearly show that the −1 isomiR is the most
abundant miR-133a-5p species in the human atrium.
Consequently, the 79T > C variant lies within the duplex
and would directly prevent base-pairing and weaken
thermostability at this site, favoring incorporation of
miR-133a-5p into RISC. Additionally the lack of base
pairing at position 79C is likely to enlarge the bulge in
the stem-loop structure, a feature known to influence
positional cleavage by Dicer and Drosha and result in in-
creased variability of 50 isomiRs [8,29]. The canonical
miRNA biosynthesis pathway predicts 3p and 5p
miRNAs of 22 nt in length, but deep sequencing studies
have revealed a surprising extent of isomiR diversity in
most tissues and species [5-8]. These isomiRs may in-
clude 50 or 30 cleavage variations, and non-templated ad-
ditions or trimming at the 30 end. It has been found that
the relative abundance and types of isomiRs in specific
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suggesting that they have distinctive biological functions
[5,8,30].
It is conventionally assumed that the seed regions are
the major determinants of target specificity, and thus it
is plausible that 50 isomiR variation can affect mRNA
target selection. For example, our group has recently
demonstrated that the two most abundant miR-133a
isomiRs in murine atrial HL-1 cells have different
targeting properties [8]. Given that each isomiR has
hundreds of mRNA targets, dynamic fluxes in isomiR
characteristics may give rise to an unexpected comple-
xity of miRNA:mRNA interactions and provide a me-
chanism for intricate regulation of gene expression in
specific tissues. To assess the potential impact of the
79T > C MIR133A2 variant, we searched for differences
in miR-133a-3p and miR-133a-5p predicted mRNA tar-
gets using the respective human and murine seed regions
and a set of genes known to be differentially regulated in
miR-133a knockout mice [21]. These results showed that
only a minority of predicted miR-133a targets were
shared, and that most were unique to either 3p or 5p
forms. With the 79T > C MIR133A2 variant, no changes
in miR-133a-3p target gene expression would be expected.
In contrast, the relative increase in miR-133a-5p could have
a relatively greater impact and give rise to selective
repression of the 5p suite of targets. It is notable that
at least 25% of the lowest-abundance miR-133a-5p
targets include mRNAs involved in regulation of tran-
scription, signaling and membrane transport. Further
studies are required to determine whether changes in
miR-133a-5p directly alter levels of these critical mo-
lecules and have biologically-significant functional
effects.
The relationship, if any, between the 79T > C
MIR133A2 variant and AF in the Family KB proband is
questionable. Although DNA samples were unavailable
from the deceased parents, it seems most likely that the
79 T > C substitution is a de novo sequence change
which was uniquely present in one family member. A
causal gene mutation that can account for the familial
pattern of AF in this kindred has yet to be identified.
The presence of the MIR133A2 variant in the Family KB
proband could foreseeably have a modifying effect by al-
tering gene expression profiles in the atrium. A number
of factors in addition to genetic variation need to be
considered in this individual, including the impact of AF
per se and of co-existent risk factors for AF. Altered ex-
pression of miR-133 itself has been observed in cardiac
tissues from patients with AF [18,19], and conditions
that predispose to AF, such as atrial dilation, ventricular
hypertrophy, and myocardial ischemia [12,31]. It is no-
table that individual II-5 had both hypertension and
valvular heart disease which independently increase AFrisk. A limitation of this study is the lack of atrial tissue
samples to document gene expression patterns in 79T
and 79C family members. The collective effects of the
multiple variables present in individual II-5 on atrial
gene expression and the electrical and structural proper-
ties of the atrial wall are difficult to predict and could
promote or protect against AF.
Conclusions
MiRNA duplex processing generates a dominant strand
that is incorporated into RISC and a passenger strand
that is usually degraded. In the normal human atrium,
almost all the miR-133a is comprised of miR-133a-3p
with negligible amounts of miR-133a-5p. Although mul-
tiple 50 and 30 isomiRs are present, there are only 2
major miR-133a-3p isomiRs and one major miR-133a-5p
isomiR. These isomiRs have distinctive suites of pre-
dicted gene targets suggesting independent biological
roles. Very few genetic variants in mature miRNA se-
quences have been reported and functionally character-
ized. We have identified a missense MIR133A2 variant
that alters miR-133a duplex processing and strand abun-
dance with accumulation of miR-133a-5p in HeLa cells.
Further studies to confirm these findings and to docu-
ment mRNA expression profiles in patient heart tissues
are indicated. Despite the importance of miR-133a in
atrial biology, miR-133a genetic variants are not a com-
mon cause of familial AF.
Methods
Genetics study subjects
One hundred and twenty subjects with suspected famil-
ial AF were identified from St Vincent’s Hospital and by
physician referral. Family probands and their relatives
were evaluated by medical history and physical examin-
ation, 12-lead echocardiography and transthoracic echo-
cardiography. A positive family history was defined as
the presence of documented AF in 2 or more first-
degree family members. Two hundred and fifty healthy
individuals with no history of cardiovascular disease
comprised a control group. All families and control sub-
jects were of Western European background. Genomic
DNA was isolated from whole blood samples using the
standard salting-out technique. Informed, written con-
sent was obtained from all participants and protocols
were approved by the St Vincent’s Hospital campus hu-
man and animal research ethics committees.
Genetic analysis
MIR1-1, MIR1-2, MIR133A1, MIR133A2, and MIR133B
were re-sequenced in DNA samples from family pro-
bands. Primer sequences were designed to amplify
regions spanning at least 120 bp upstream and down-
stream of the stem-loop sequences (as annotated by
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hsa-miR-133a-2, hsa-miR-133b (miRBase accession num-
bers MI0000651, MI0000437, MI0000450, MI0000451,
MI0000822, respectively). Polymerase chain reaction
(PCR) was carried out on genomic DNA using FastStart
Taq DNA Polymerase (Roche, Indianapolis, IN, USA) on
a Dyad Peltier Thermal Cycler (Bio-Rad Laboratories,
Hercules, CA, USA) with the primer pairs shown in
Table 2, designed using the programs Primer3Plus and
Amplify version 3.1.4 (University of Wisconsin, Madison,
WI, USA). Cycling conditions for MIR1-1, MIR133A2
and MIR133B are as follows: 94°C (3 min), then 35 cy-
cles of 94°C (20 s), 55°C (30 s), 72°C (60 s) and finally
72°C (8 min). MIR1-2 and MIR133A1 were amplified
using the “Slowdown PCR” method. Amplicons were puri-
fied with ExoSAP-IT enzyme (GE Healthcare, Chalfont St
Giles, Buckinghamshire, UK), sequenced using Big Dye
Terminator (version 3.1, Applied Biosystems, Foster City,
CA, USA) and analyzed on an ABI PRISM 3700 DNA
Analyzer (The Ramaciotti Centre for Gene Function Ana-
lysis, UNSW, Sydney, New South Wales, Australia). View-
ing and analysis of the data was carried out using the
DNASTAR software package (Madison, WI, USA). DNA
sequence variants were validated by re-sequencing inde-
pendent PCR-generated amplicons from probands in both
directions. Sequence variants identified in family probands
were subsequently evaluated in affected and unaffected
family members and in the cohort of healthy control
subjects.
Plasmid constructs and cell transfections
A 272bp fragment containing the precursor sequence of
mature miR-133a-2 with 79T and 79C alleles was ampli-
fied from genomic DNA using gene-specific primers
containing BamHI and HindIII restriction enzyme sites
(underlined): forward: 50- ggggcggccgcggatccatctccatcgg
gactgc -30, reverse: 50- gggaagcttggcactcagggcttcactta -30.Table 2 Primer sequences used for PCR amplification and
sequencing
Primer
name
Primer sequence Amplicon
size (bp)
Sequencing
primer
mir-1-1F 50- gagatggattcagggatgga -30 494 mir-1-1R
mir-1-1R 50- acctgctgacacaggcaaag -30
mir-1-2F 50- ggaaccattaatgccatgct -30 467 mir-1-2F
mir-1-2R 50- tgaaatctacttcactggatcttctt -30
mir-133a-1F 50- tttaaaccattaagcgcagga -30 455 mir-133a-1F
mir-133a-1R 50- ttgaaatccttaagtcatccataca -30
mir-133a-2F 50- ctgcagagcttgagggaaac -30 466 mir-133a-2R
mir-133a-2R 50- caaggaggaacaagcaggag -30
mir-133bF 50- agtcatgcaacatgaaatacaaa -30 500 mir-133bR
mir-133bR 50- gagtgcaaaggcacagaaca -30Amplification was carried out using FastStart Taq DNA
Polymerase with the same cycling condictions as de-
scribed for MIR1-1, MIR133A2 and MIR133B above.
PCR amplicons were purified using the QIAquick Gel
Extraction Kit (Qiagen, Hildem, Germany) and cloned
into the pGEMW-T Easy Vector system (Promega,
Fitchburg, WI, USA) according to manufacturer’s instruc-
tions. Clones were digested with BamHI and HindIII and
ligated to BamHI- and HindIII-digested pSilencerTM puro
4.1-CMV vector (Applied Biosystems). All plasmid con-
structs were confirmed by sequencing.
HeLa cells (ATCC, Manassas, VA, USA) were maintained
in Dulbecco’s modified eagle medium (DMEM) with 5%
fetal calf serum, supplemented with glutamine and
penicillin-streptomycin. Cells were seeded in a 6-well plate
8 hours before transfection. Transfections were performed
in duplicate at ~70% confluency by adding 1.5mL of
DMEM and 1mL of transfection solution per well. The
1mL transfection solution contained Opti-MEMW, 150ng
of 79T or 79C constructs and 5uL of Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA, USA), which was incu-
bated for 20 minutes at room temperature prior to
transfection.
RNA analysis
HeLa cells (ATCC) were harvested after 24 hours and
total RNA was extracted using TRIzolW (Invitrogen).
Total RNA (5ug) was separated on 5% stacking/12% re-
solving polyacrylamide gels, transferred electrophoretic-
ally to Gene Screen PlusW Hybridization Transfer
Membranes (Perkin Elmer, Waltham, MA, USA). Sepa-
rated RNA was fixed on the membranes by ~20 sec UV
crosslinking on a UV Stratalinker 2400 (Stratagene,
Santa Clara, Ca, USA). Northern blotting was performed
as described [32]. DNA oligonucleotide probes (50- taca
gctggttgaaggggaccaaa -30, 50- gatttggttccattttaccagct -30, 50-
tgtgctgccgaagcaagcac -30) complementary to mature miR-133a
(miR-133a-3p), passenger miR-133a (miR-133a-5p) and
U6 sequences, respectively, were end-labeled with 32P using T4
Polynucleotide Kinase (New England Biolabs, Ipswich,
MA, USA) and purified by Microspin G-25 columns
(GE Healthcare) according to manufacturer’s instruc-
tions. A single probe was incubated with the mem-
brane in hybridization buffer (250mM NaPO4, 7%
SDS, pH 7) at 42°C overnight. After hybridization,
membranes were washed 3 times with 2xSSC (1.753%
NaCl, 0.882% Na3C6H5O7) at 42°C, and exposed over-
night. Phosphorimaging was performed on a Fuji
imager (FLA-5100, Fujifilm, Minato-ku, Tokyo, Japan).
Hybridization signals were quantified using Multi Gauge
v2.3 software (Fujifilm, Minato-ku, Tokyo, Japan) and the
values measured for each probe from each blot were
scaled to the average signal. The scaled miR-133a values
were then normalized to the scaled U6 values to adjust for
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the Mann–Whitney U test with a P value <0.05 deemed
significant.
Deep sequencing
For deep sequencing of atrial myocardium, total RNA was
extracted using the miRNeasyW Kit (QIAGEN, Hildem,
Germany) from right atrial appendage samples obtained
from two males aged 62 and 64 years with no history of
AF who underwent coronary artery bypass graft surgery.
Atrial tissue was also obtained from the hearts of 3 wild-
type mice aged 4–6 weeks. Small RNA libraries were cre-
ated using NEBNextW small RNA library preparation kit
(New England Biolabs, Ipswich, MA, USA) and sequenced
on a 5500 SOLiDTM platform (Applied Biosystems).
Sequencing data were mapped using Lifescope software
(Applied Biosystems). Processed miRNA counts were
initially collated from all tags that aligned within 3
nt of the miRBase defined 50 starting position. Tags
that mapped to miRBAse v18 can be accessed via a
“miRDSPRing” document (D. Humphreys, manuscript in
preparation) and are available in the Supporting Informa-
tion (Tables S1 and S2).
MiRNA target predictions
Gene targets for human and murine miR133a were
predicted using TargetScan Custom (v5.2) [33] with the
“seeds” (nt 2–8) of the most abundant miR-133a-3p and
miR-133a-5p isomiRs that were identified via deep sequen-
cing used as inputs. The newer version of TargetsScan
(v6.2) and a range of other commonly-used publically-
available target prediction programs (DIANA-microT,
Microinspector, microRNA.org, MirTarget2, PicTar, PITA,
RNA22, RNAhybrid) were unable to be utilized because
human and/or murine miR-133a-5p sequences were unable
to be inputted and/or analyzed. Predicted gene targets of
murine miR-133a were matched against mRNAs that in
which expression levels were altered by at least 1.5 fold in
microarray data from miR-133a knockout mice [21]. The
TargetScan outputs for human miR-133a-3p and miR-133a
-5p were imported into Ingenuity Pathway Analysis soft-
ware (IngenuityW Systems, www.ingenuity.com) for identifi-
cation of biological pathways in the heart that might be
differentially regulated (Additional file 5: Table S5).
Additional files
Additional file 1: Table S1. Alignment of tags derived from mouse
atria with miRNA hairpins as listed in miRBase version 18.
Additional file 2: Table S2. Alignment of tags derived from human
right atrial appendage with miRNA hairpins as listed in miRBase
version 18.
Additional file 3: Table S3. Sequences and abundance of different 50
and 30 murine miR-133a isomiRs identified by sequencing of murine atria.Additional file 4: Table S4. Sequences and abundance of different 50
and 30 human miR-133a isomiRs identified by sequencing of human atria.
Additional file 5: Table S5. TargetScan outputs for human miR-133a-3p
and miR-133a-5p (from Figure 2C) that were used as inputs for Ingenuity
Pathway Analysis.
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